Form 4: REGENXBIO Executive Reports Stock Transactions

REGENXBIO Inc. executive Curran Simpson reports transactions related to the Employee Stock Purchase Plan and tax withholdings for restricted stock units.

Summary

• Curran Simpson, Chief Executive Officer and Director of REGENXBIO Inc., has filed a Form 4 detailing recent transactions.
• These transactions include the acquisition of common stock through the Employee Stock Purchase Plan (ESPP) for two purchase periods: July 1, 2025, to December 31, 2025, and January 1, 2026, to June 30, 2026.
• Additionally, shares were withheld to cover taxes upon the vesting of restricted stock units granted on July 1, 2024.
• The ESPP purchases were made at 85% of the closing stock price on the respective purchase period end dates.
• Following these transactions, Simpson beneficially owns 338,053 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reflects standard executive compensation practices and employee stock purchase participation, indicating ongoing engagement and potential confidence in the company.

Positives

• Executive participation in the Employee Stock Purchase Plan indicates confidence in the company's future performance.
• Acquisition of shares at a discount (85% of closing price) through the ESPP is a benefit for the executive.
• Vesting of restricted stock units and subsequent tax withholding suggest that performance milestones or time-based vesting conditions have been met.

Negatives

• Withholding of shares for tax purposes represents a reduction in the executive's direct shareholding, although it is a standard practice.

Risks

• The filing does not explicitly mention any new risks or challenges.
• Potential future tax implications for executives related to stock-based compensation remain a general consideration.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. However, participation in the ESPP and vesting of RSUs generally implies a positive outlook from management regarding the company's long-term prospects.

Management Comments

• The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is exempt under Rule 16b-3(c).
• In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025.
• The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is exempt under Rule 16b-3(c).
• In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2026.
• Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on July 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on July 1, 2026.

Industry Context

StockSavvy.ai notes that executive participation in ESPPs and the use of stock-based compensation are common practices across the biotechnology and pharmaceutical sectors, reflecting alignment of executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The transactions do not directly impact the overall share count or company financials but reflect executive commitment.
• Employees: Participation in the ESPP is a benefit for employees, including executives.
• Management: The transactions are part of standard executive compensation and incentive structures.

Next Steps

• Continued reporting of stock transactions by insiders as required by SEC regulations.
• Potential future vesting and tax implications for other stock-based awards.

Key Dates

Keywords

REGENXBIO, RGNX, Form 4, Stock Purchase Plan, ESPP, Restricted Stock Units, Insider Trading, Executive Compensation, Beneficial Ownership, SEC Filing